All In Biotech

Drug Trial Radar · NCT07018713

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Chronic Migraine

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 808 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

808

Actual

Start

Aug 21, 2025

Primary completion

Mar 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Merz Therapeutics GmbHIndustry
Sponsor type
Industry
First posted
Jun 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.

Conditions

  • Chronic Migraine

Interventions

  • XeominDrug

    Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)

  • PlaceboDrug

    Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in monthly migraine days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose ATime frame: Baseline to month 6

Locations

111 sites in 13 countries. Site status is shown where the registry gives one.

  • TrialSphere Corp, Merz Investigational Site #0010513

    Chandler, Arizona

  • Arizona Neuroscience Research, Merz Investigational Site #0010521

    Phoenix, Arizona

  • Baptist Health Medical Center, Merz Investigational Site #0010520

    Little Rock, Arkansas

  • Chemidox Clinical Trials Inc, Merz Investigational Site #0010488

    Lancaster, California

  • Clinical Research Institute, Merz Investigational Site #0010487

    Los Angeles, California

  • BNL Health, Merz Investigational Site #0010501

    Los Angeles, California

  • Clinical Trials Management Services, Merz Investigational Site #0010526

    Thousand Oaks, California

  • Hasbani Neurology, Merz Investigational Site #0010509

    New Haven, Connecticut

  • Yale Center for Clinical Investigations, Merz Investigational Site #0010527

    New Haven, Connecticut

  • New England Institute Neurology and Headache, Merz Investigational Site #0010441

    Stamford, Connecticut

  • Northwest Florida Clinical Research Group, Merz Investigational Site #0010286

    Gulf Breeze, Florida

  • Nexus Clinical Research Center, Merz Investigational Site #0010514

    Homestead, Florida

  • Jacksonville Center for Clinical Research, Merz Investigational Site #0010515

    Jacksonville, Florida

  • Clinical Research of Central Florida, Merz Investigational Site #0010532

    Lakeland, Florida

  • University of Miami Miller School of Medicine, Merz Investigational Site #0010493

    Miami, Florida

  • American Research Institute, Merz Investigational Site #0010492

    Miami, Florida

  • Premiere Research Institute at Palm Beach Neurology, Merz Investigational Site #0010499

    West Palm Beach, Florida

  • Accel Research - NeuroStudies, Merz Investigational Site #0010523

    Decatur, Georgia

  • Hawaii Pacific Neuroscience, Merz Investigational Site #0010510

    Honolulu, Hawaii

  • Kansas Institute of Research,, Merz Investigational Site #0010495

    Overland Park, Kansas

  • Crescent City Headache and Neurology Center, Merz Investigational Site #0010517

    Chalmette, Louisiana

  • DelRicht Clinical Research, Merz Investigational Site #0010518

    New Orleans, Louisiana

  • Sinai Hospital of Baltimore, Merz Investigational Site #0010505

    Baltimore, Maryland

  • MedVadis Research, Merz Investigational Site #0010524

    Waltham, Massachusetts

  • Mass Institute of Clinical Research, Merz Investigational Site #0010506

    Westborough, Massachusetts

  • Vida Clinical Studies, Merz Investigational Site #0010498

    Dearborn Heights, Michigan

  • Quest Research Institute, Merz Investigational Site #0010484

    Farmington Hills, Michigan

  • Mayo Clinic, Merz Investigational Site #0010212

    Rochester, Minnesota

  • StudyMetrix Research, Merz Investigational Site #0010530

    City of Saint Peters, Missouri

  • Quality Clinical Research, Merz Investigational Site #0010522

    Omaha, Nebraska

  • Dent Neurosciences Research Center, Merz Investigational Site #0010486

    Amherst, New York

  • Integrative Clinical Trials, Merz Investigational Site #0010496

    Brooklyn, New York

  • New York Neurology Associates, Merz Investigational Site #0010500

    New York, New York

  • True North Neurology, Merz Investigational Site #0010508

    Port Jefferson Station, New York

  • Rochester Clinical Research, Merz Investigational Site #0010512

    Rochester, New York

  • Upstate Clinical Research Associates, Merz Investigational Site #0010485

    Williamsville, New York

  • Dayton Center for Neurological Disorders, Merz Investigational Site #0010531

    Centerville, Ohio

  • Headache Center of Hope, Merz Investigational Site #0010528

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center, Merz Investigational Site #0010491

    Cleveland, Ohio

  • Tekton Research, Merz Investigational Site #0010494

    Edmond, Oklahoma

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.